SIRT6 and fatty liver disease: Collectively, these data demonstrate that attenuation of hepatic steatosis by RGZ is likely mediated by the activation of the Sirt6-AMPK pathway, suggesting Sirt6 as a therapeutic target for hepatic steatosis and its related diseases.